2019: Hepatitis C Care Expanded

On This Day in Health: April 30, 2019

On April 30, 2019, the U.S. Food and Drug Administration expanded the approved use of Mavyret, a combination of glecaprevir and pibrentasvir, to eligible pediatric patients with chronic hepatitis C. The medicine had previously been approved for adults in 2017. The new labeling covered patients aged 12 years and older or weighing at least 45 kilograms, under the specified conditions of use. It provided an option covering all six hepatitis C viral genotypes in patients without cirrhosis or with compensated cirrhosis. The event was an extension of an existing treatment to a younger population, rather than the original discovery or approval of the medicine.

Hepatitis C is a viral infection that can cause inflammation and lasting damage in the liver. Chronic infection may eventually impair liver function. Direct-acting antiviral medicines target parts of the virus’s replication process, reducing its ability to multiply. Mavyret combined a protease inhibitor with an inhibitor of the viral NS5A protein. Those complementary targets helped explain the medicine’s role across different viral genotypes. Its significance for adolescents was the opportunity to treat chronic infection with an oral regimen whose use had now been evaluated for that population. Age and weight criteria mattered because adult evidence alone does not automatically establish suitable treatment for every child.

The pediatric evidence included an open-label trial of 47 adolescents aged 12 to 18 years. The FDA’s pediatric labeling summary described participants without cirrhosis, including 36 who had not previously received treatment and 11 who had treatment experience. They received courses lasting eight or 16 weeks. No hepatitis C virus was detected in the blood 12 weeks after treatment among the patients reported in the approval announcement. This outcome, called sustained virologic response, is used to assess cure of the infection. The result was encouraging, while the study’s size and design remained important context. Other eligible clinical situations and genotypes also drew support from comparable drug exposures and previous adult evidence.

The April decision expanded access to a treatment strategy aimed at clearing the virus, but it did not remove the need for careful assessment. The FDA highlighted the risk of hepatitis B reactivation in people with both infections, as well as liver-related limitations and medication interactions. Treatment duration depended on the clinical circumstances rather than a single schedule for everyone. The extension also should not be confused with the separate, later approval for younger children. April 30 marks a concrete step in bringing antiviral progress to adolescents: an established combination gained a pediatric indication supported by new evidence. Its place in health history reflects the work required to extend a successful adult therapy responsibly, with the population, outcomes and conditions of use clearly defined.